Page 35 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine Brachytherapy versus external beam in local dose escalation

and treatment delivery to post-treatment follow-up and Consent for publication
management of potential complications.
Not applicable.
Technological and procedural advancements have
progressively refined IRT, transforming it into a highly Availability of data
precise and internationally recognized therapeutic option, Not applicable.
with an improved therapeutic index. Looking ahead,
the integration of personalized oncology and advanced References
imaging technologies is anticipated to further enhance the 1. Suntharalingam N, Podgorsak EB, Tölli H. Brachytherapy:
clinical effectiveness and precision of IRT. Nevertheless, Physical and clinical aspects. In: Radiation Oncology Physics:
despite the growing body of clinical evidence and A Handbook for Teachers and Students. Vienna: International
significant technological progress, utilization patterns of Atomic Energy Agency; 2005. p. 451-484.
IRT remain inconsistent across institutions and regions.
2. Fröhlich G, Mészáros N, Smanykó V, et al. Is stereotactic
Healthcare policymakers and insurance systems cyberknife radiotherapy or multicatheter HDR brachytherapy
should be encouraged to support optimized care delivery the better option dosimetrically for accelerated partial breast
models that ensure equitable access to guideline-based irradiation? Brachytherapy. 2021;20(2):326-331.
treatments and empower patients to choose among doi: 10.1016/j.brachy.2020.10.003
appropriate therapeutic options. Considering increasing 3. Gielda BT, Shah AP, Marsh JC, et al. Helical tomotherapy
healthcare expenditures, the proven cost-effectiveness delivery of an IMRT boost in lieu of interstitial brachytherapy
of IRT should be recognized as a compelling rationale in the setting of gynecologic malignancy: Feasibility and
for the development of clear implementation guidelines dosimetric comparison. Med Dosim. 2011;36(2):206-212.
and sustained investment in professional training and doi: 10.1016/j.meddos.2010.03.005
education. Although survival data specific to IRT remain
limited, its demonstrated potential to improve definitive 4. Shwetha B, Ravikumar M, Palled SR, Supe SS, Sathiyan S.
cure rates underscores its substantial clinical value. Dosimetric comparison of high dose rate brachytherapy
and intensity-modulated radiation therapy for cervical
Acknowledgments carcinoma. J Med Phys. 2011;36(2):111-116.
doi: 10.4103/0971-6203.79687
None.
5. Akiyama H, Pesznyák C, Béla D, et al. Image guided high-
Funding dose-rate brachytherapy versus volumetric modulated arc
therapy for head and neck cancer: A comparative analysis of
None. dosimetry for target volume and organs at risk. Radiol Oncol
2018;52(4):461-467.
Conflict of interest
doi: 10.2478/raon-2018-0042
Gyoergy Kovacs and Luca Tagliaferri are members of the
Editorial Board of this journal but were not involved in any 6. Major T, Fröhlich G, Ágoston P, Polgár C, Takácsi-Nagy Z.
The value of brachytherapy in the age of advanced external
way, directly or indirectly, in the editorial and peer-review beam radiotherapy: A review of the literature in terms of
process for this paper. Separately, the other authors declare dosimetry. Strahlenther Onkol. 2021;198(2):93-109.
that they have no known competing financial interests or
personal relationships that could have influenced the work doi: 10.1007/s00066-021-01867-1
reported in this paper. 7. Ullah A, Ullah N, Nawaz T, Aziz T. Molecular mechanisms
of sanguinarine in cancer prevention and treatment.
Author contributions Anticancer Agents Med Chem. 2023;23(7):765-778.
Conceptualization: Maria A. Gambacorta, Luca Tagliaferri, doi: 10.2174/1871520622666220831124321
Gyoergy Kovacs 8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020
Writing–original draft: Valentina Lancellotta, Maria C. La statement: An updated guideline for reporting systematic
Milia, Natalia Barogi reviews. BMJ. 2021;372:71.
Writing–review & editing: Maria A. Gambacorta, Luca doi: 10.1136/bmj.n71
Tagliaferri, Gyoergy Kovacs
9. Ciabattoni A, Gregucci F, Fastner G, et al. IOERT versus
Ethics approval and consent to participate external beam electrons for boost radiotherapy in stage I/
II breast cancer: 10-year results of a phase III randomized
Not applicable. study. Breast Cancer Res. 2021;23(1):46.

Volume 3 Issue 3 (2025) 27 doi: 10.36922/ARNM025160017